Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other financing activities: 2020-2024

Historic Other financing activities for Compass Therapeutics (CMPX) over the last 5 years, with Dec 2024 value amounting to $543,000.

  • Compass Therapeutics' Other financing activities rose 431800.00% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 2868.04%. This contributed to the annual value of $543,000 for FY2024, which is 441.51% up from last year.
  • Per Compass Therapeutics' latest filing, its Other financing activities stood at $543,000 for FY2024, which was up 441.51% from -$159,000 recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Other financing activities registered a high of $6.3 million during FY2020, and its lowest value of -$159,000 during FY2023.
  • Over the past 3 years, Compass Therapeutics' median Other financing activities value was $495,000 (recorded in 2022), while the average stood at $293,000.
  • In the last 5 years, Compass Therapeutics' Other financing activities crashed by 132.12% in 2023 and then surged by 441.51% in 2024.
  • Compass Therapeutics' Other financing activities (Yearly) stood at $6.3 million in 2020, then slumped by 95.55% to $281,000 in 2021, then spiked by 76.16% to $495,000 in 2022, then tumbled by 132.12% to -$159,000 in 2023, then soared by 441.51% to $543,000 in 2024.